Home > Cytochromes P450 (CYPs) & > Abiraterone Acetate

Abiraterone Acetate

乙酸阿比特龙酯,CB-7630,CB7630,CB 7630

Abiraterone Acetate是Abiraterone的醋酸盐形式，是一种甾体类细胞色素CYP17抑制剂，IC50为72 nM。

目录号
EY0293
EY0293
EY0293
EY0293
纯度
99.53%
99.53%
99.53%
99.53%
规格
1 mg
5 mg
10 mg
50 mg
原价
150
320
525
725
售价
150
320
525
725
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Abiraterone Acetate is an acetate salt form of Abiraterone which is a steroidal cytochrome CYP17 inhibitor with IC50 of 72 nM in a cell-free assay.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0 μM -10 μM

  • 动物实验

    0.5 mmol/kg/d皮下注射给药

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Pinto-Bazurco Mendieta MA, et al. J Med Chem. 2008, 51(16), 5009-5018.
    [2] Ang, J.E., et al. 2009. Br. J. Cancer. 100: 671-675.
    [3] O'Donnell, A., et al. 2004. Br. J. Cancer. 90: 2317-2325.
    [4] Latorre, R., et al. 2007. Cell Calcium. 42: 427-438.
    [5] Ideyama, Y., et al. 1998. Prostate. 37: 10-18.

    分子式
    C26H33NO2    		 分子量
    391.55    		 CAS号
    154229-18-2    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    2 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    28 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT01495910 21-hydroxylase Deficiency Drug: Abiraterone acetate Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2011-12-01 2014-02-27
    NCT01199146 Prostate Cancer Drug: Abiraterone acetate University of California, San Francisco|Johnson & Johnson|Cougar Biotechnology, Inc. Phase 2 2010-09-01 2015-10-02
    NCT01735396 Prostate Cancer Drug: Abiraterone Acetate Icahn School of Medicine at Mount Sinai Phase 2 2012-12-01 2017-01-09
    NCT02608359 Prostate Cancer Drug: Abiraterone Acetate Johnson & Johnson Private Limited 2016-05-31 2017-03-12
    NCT00473512 Prostatic Neoplasms Drug: Abiraterone acetate|Drug: Abiraterone acetate MTD|Drug: Dexamethasone Cougar Biotechnology, Inc. Phase 1|Phase 2 2005-11-01 2014-02-27
    NCT02001571 Prostate Cancer Drug: Abiraterone acetate Cougar Biotechnology, Inc. Phase 1 2009-08-01 2013-11-28
    NCT00910754 Prostate Neoplasms Drug: Abiraterone acetate|Drug: Prednisone Janssen Research & Development, LLC Phase 1 2009-05-01 2013-04-11
    NCT01717898 Castrate-resistant Prostate Cancer Patients. Drug: BEZ235|Drug: Prednisone|Drug: Abiraterone acetate Charles Ryan|Novartis Pharmaceuticals|University of California, San Francisco Phase 1|Phase 2 2013-01-01 2015-10-01
    NCT01517802 Metastatic Castration-resistant Prostate Cancer|Metastatic Breast Cancer Drug: Abiraterone acetate|Drug: Prednisone Janssen Research & Development, LLC Phase 3 2012-03-01 2017-03-01
    NCT00485303 Prostatic Neoplasms|Prostate Cancer Drug: Abiraterone acetate|Drug: Prednisone Cougar Biotechnology, Inc. Phase 2 2007-06-01 2013-06-25
    NCT01842321 Breast Cancer Drug: Abiraterone Acetate UNICANCER Phase 2 2013-07-01 2016-03-17
    NCT01543776 Castration-resistant Prostate Cancer|Stage IV Prostate Cancer Drug: abiraterone acetate University of Chicago|National Cancer Institute (NCI) Phase 2 2012-01-01 2017-02-01
    NCT02230046 Healthy Drug: Abiraterone acetate (Treatment A)|Drug: Abiraterone acetate (Treatment B)|Drug: Abiraterone acetate (Treatment B) Janssen Research & Development, LLC Phase 1 2014-10-01 2016-01-18
    NCT01393730 Prostate Cancer Drug: Abiraterone acetate|Drug: Dutasteride|Drug: Prednisone Mary-Ellen Taplin, MD|Dana-Farber Cancer Institute Phase 2 2011-09-01 2016-09-12
    NCT01637402 Castration Resistant Prostate Cancer Drug: Abiraterone Acetate|Drug: Prednisone Terence Friedlander, MD|Janssen, LP|University of California, San Francisco Phase 2 2013-03-01 2016-05-20
    NCT01314118 Prostate Cancer|Prostatic Neoplasm Drug: abiraterone acetate in combination with prednisone Janssen Biotech, Inc. Phase 2 2011-05-01 2017-02-03
    NCT01715259 Renal Insufficiency Drug: Abiraterone acetate: participants with end-stage renal disease|Drug: Abiraterone acetate: matched control participants with normal renal function Cougar Biotechnology, Inc. Phase 1 2009-08-01 2012-11-16
    NCT02867852 Salivary Glands Tumors Drug: Abiraterone acetate Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Phase 2 2015-03-01 2016-08-22
    NCT00474383 Prostate Neoplasms Drug: Abiraterone acetate|Drug: Glucocorticoid Cougar Biotechnology, Inc. Phase 2 2006-11-01 2014-04-10

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：